ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Vertex signs viral vector R&D pact with Affinia

by Michael McCoy
May 2, 2020 | APPEARED IN VOLUME 98, ISSUE 17

 

Vertex Pharmaceuticals and Affinia Therapeutics have formed a pact to research engineered adeno-associated virus capsids for delivering gene therapies. Affinia will get $80 million in up-front and research payments to create capsids that deliver Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis treatments. Affinia launched in March with $60 million in series A financing. It’s based on technology developed at the Grousbeck Gene Therapy Center.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment